KevinRobertFlahertyMDMS
Pulmonology • Ann Arbor, MICritical Care Medicine, Pleural Disease
Associate Professor, Internal Medicine, University of Michigan Medical School
Dr. Flaherty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000Fax+1 734-615-5348
Education & Training
University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1997- Indiana University School of MedicineClass of 1993
Certifications & Licensure
MI State Medical License 1997 - 2025
IN State Medical License 1994 - 2003- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis Start of enrollment: 2003 Mar 01
- Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2009 Dec 01
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial.Steven D Nathan, Natasa Rajicic, Rosemarie Dudenhofer, Rahat Hussain, Rahul Argula
Annals of the American Thoracic Society. 2024-12-01 - Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study.Lisa Lancaster, Vincent Cottin, Murali Ramaswamy, Wim A Wuyts, R Gisli Jenkins
Therapeutic Advances in Respiratory Disease. 2024-11-08 - Acute exacerbations in patients with progressive pulmonary fibrosis.Michael Kreuter, Elizabeth A Belloli, Elisabeth Bendstrup, Stefania Cerri, Kevin R Flaherty
ERJ Open Research. 2024-11-01
Journal Articles
- Quantitative HRCT Fibrosis Score: Performance Characteristics in Idiopathic Pulmonary FibrosisMarvin I Schwarz, Kevin R Flaherty, Ganesh Raghu, The European Respiratory Journal
- Stability or Improvement in Forced Vital Capacity with Nintedanib in Patients with IPFKevin R Flaherty, Craig S Conoscenti, The European Respiratory Journal
Other
- Nonspecific interstitial pneumoniaFlaherty KR
http://www.uptodate.com/contents/nonspecific-interstitial-pneumonia
UpToDate, Wolters Kluwer Health - 2012-05-11
Press Mentions
If Biopsy Needed for ILD Diagnosis, Start with Less-Invasive Option, Trial SuggestsApril 21st, 2024
New Analyses of Ofev® Data in Patients with Chronic Fibrosing ILDs Available During American Thoracic Society CongressAugust 5th, 2020
Nintedanib Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive PhenotypeMarch 18th, 2020- Join now to see all
Grant Support
- Forging A Road To Personalized Medicine In Interstitial Lung DiseasesNational Heart, Lung, And Blood Institute2012
- Longitudinal, Computer Assisted Analysis In IPFNational Heart, Lung, And Blood Institute2008–2011
- Ctrip: Molecular Phenotypes Of Rapidly Progressive Idiopathic Pulmonary FibrosisNational Heart, Lung, And Blood Institute2009–2010
- Phase I/II Trial Tetrathiomolybdate (TM) In PTS W/ Usual Interstitial PneumoniaNational Center For Research Resources2004–2007
- Prognostication In Idiopathic Interstitial PneumoniaNational Heart, Lung, And Blood Institute2002–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
